BioArctic AB
Stockholm Stock ExchangeTotal Valuation
BioArctic AB carries a market capitalization of 28.92B, placing it among publicly traded companies globally. Its enterprise value stands at 26.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 28.92B |
| Enterprise Value | 26.36B |
Share Statistics
BioArctic AB currently has 88.72M shares outstanding.
| Shares Outstanding | 88.72M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
BioArctic AB trades at a trailing price-to-earnings ratio of 132.95.
| PE Ratio | 132.95 |
| PS Ratio | 24.72 |
| PB Ratio | N/A |
| P/TBV Ratio | 12.90 |
| P/FCF Ratio | 22.64 |
| P/OCF Ratio | 22.62 |
Enterprise Valuation
On an enterprise value basis, BioArctic AB trades at an EV/EBITDA multiple of 66.84 and an EV/FCF ratio of 20.82. The EV/Sales ratio of 22.98 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 66.84 provides insight into valuation relative to core operating earnings.
| EV / Sales | 22.98 |
| EV / EBITDA | 66.84 |
| EV / EBIT | 66.84 |
| EV / FCF | 20.82 |
Financial Position
BioArctic AB maintains a current ratio of 6.54, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.85, indicating elevated leverage, while an interest coverage ratio of 16.30 demonstrates strong ability to service its debt obligations.
| Current Ratio | 6.54 |
| Quick Ratio | 5.12 |
| Debt / Equity | 1.85 |
| Debt / EBITDA | 0.10 |
| Interest Coverage | 16.30 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 8.88 |
| Return on Invested Capital (ROIC) | 9.62 |
| Return on Capital Employed (ROCE) | 492.14 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, BioArctic AB has paid 200.49M in income taxes, reflecting an effective tax rate of 48.46.
| Income Tax | 200.49M |
| Effective Tax Rate | 48.46 |
Stock Price Statistics
BioArctic AB's stock has gained approximately 75.76737% over the past 52 weeks. The 50-day moving average sits at 317.18, while the 200-day moving average is 312.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | 75.76737% |
| 50-Day Moving Average | 317.18 |
| 200-Day Moving Average | 312.02 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, BioArctic AB generated 1.15B in revenue and converted that into 213.24M in net income, yielding earnings per share of 2.41. EBITDA reached 394.35M, while operating income came in at 394.35M.
| Revenue | 1.15B |
| Gross Profit | 1.08B |
| Operating Income | 394.35M |
| Pretax Income | 413.73M |
| Net Income | 213.24M |
| EBITDA | 394.35M |
| EBIT | 394.35M |
| Earnings Per Share (EPS) | 2.41 |
Balance Sheet
BioArctic AB holds 2.03B in cash and equivalents against 40.74M in total debt, resulting in a net debt position of -1.20B.
| Cash & Cash Equivalents | 2.03B |
| Total Debt | 40.74M |
| Net Debt | -1.20B |
| Equity (Book Value) | N/A |
| Book Value Per Share | N/A |
| Working Capital | 2.20B |
Cash Flow
BioArctic AB produced 1.25B in operating cash flow over the past twelve months.
| Operating Cash Flow | 1.25B |
| Capital Expenditures | N/A |
| Free Cash Flow | 1.25B |
| FCF Per Share | 14.15 |
Margins
BioArctic AB operates with a gross margin of 94.13, reflecting its pricing power and cost economics. The operating margin of 34.38 and net profit margin of 18.59 provide insight into operational efficiency.
| Gross Margin | 94.13 |
| Operating Margin | 34.38 |
| Pretax Margin | 36.07 |
| Profit Margin | 18.59 |
| EBITDA Margin | 34.38 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.09 |
| FCF Yield | 4.42 |
Scores
BioArctic AB posts an Altman Z-Score of 37.25, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 37.25 |